Brokerages predict that uniQure N.V. (NASDAQ:QURE) will post $2.92 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for uniQure N.V.’s earnings. The lowest sales estimate is $2.38 million and the highest is $3.59 million. uniQure N.V. reported sales of $1.82 million during the same quarter last year, which would suggest a positive year over year growth rate of 60.4%. The business is expected to issue its next earnings report on Thursday, August 24th.

On average, analysts expect that uniQure N.V. will report full year sales of $2.92 million for the current year, with estimates ranging from $11.90 million to $17.47 million. For the next fiscal year, analysts anticipate that the company will post sales of $28.48 million per share, with estimates ranging from $18.53 million to $35.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow uniQure N.V..

uniQure N.V. (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.16. The firm had revenue of $3.32 million for the quarter, compared to analyst estimates of $4.20 million. uniQure N.V. had a negative return on equity of 103.26% and a negative net margin of 223.38%.

A number of research analysts have weighed in on QURE shares. Zacks Investment Research lowered uniQure N.V. from a “buy” rating to a “sell” rating in a report on Wednesday, May 17th. ValuEngine raised uniQure N.V. from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Jefferies Group LLC reaffirmed a “hold” rating and set a $8.00 target price on shares of uniQure N.V. in a report on Wednesday, April 12th. Oppenheimer Holdings, Inc. set a $17.00 target price on uniQure N.V. and gave the company a “buy” rating in a report on Tuesday, May 16th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of uniQure N.V. in a report on Wednesday, May 24th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. uniQure N.V. presently has a consensus rating of “Hold” and a consensus target price of $14.61.

ILLEGAL ACTIVITY WARNING: This article was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/brokerages-expect-uniqure-n-v-qure-will-post-quarterly-sales-of-2-92-million.html.

In other news, insider Harald Petry sold 58,075 shares of the business’s stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $6.01, for a total transaction of $349,030.75. Following the completion of the transaction, the insider now owns 155 shares of the company’s stock, valued at $931.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 173,460 shares of company stock valued at $1,042,986 in the last three months. 0.64% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the company. FMR LLC raised its stake in shares of uniQure N.V. by 4.1% in the fourth quarter. FMR LLC now owns 1,175,118 shares of the biotechnology company’s stock valued at $6,580,000 after buying an additional 46,200 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of uniQure N.V. by 6.8% in the fourth quarter. Renaissance Technologies LLC now owns 251,300 shares of the biotechnology company’s stock valued at $1,407,000 after buying an additional 15,950 shares in the last quarter. Oxford Asset Management purchased a new stake in shares of uniQure N.V. during the first quarter valued at about $100,000. JPMorgan Chase & Co. raised its stake in shares of uniQure N.V. by 50.5% in the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock valued at $253,000 after buying an additional 14,702 shares in the last quarter. Finally, P.A.W. Capital Corp purchased a new stake in shares of uniQure N.V. during the first quarter valued at about $867,000. 30.22% of the stock is owned by institutional investors and hedge funds.

About uniQure N.V.

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Get a free copy of the Zacks research report on uniQure N.V. (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for uniQure N.V. (NASDAQ:QURE)

Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.